These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30920790)

  • 1. Insight into Novel Treatment for Cognitive Dysfunctions across Disorders.
    Prevot TD; Li G; Cook JM; Sibille E
    ACS Chem Neurosci; 2019 May; 10(5):2088-2090. PubMed ID: 30920790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment.
    Koh MT; Rosenzweig-Lipson S; Gallagher M
    Neuropharmacology; 2013 Jan; 64(1):145-52. PubMed ID: 22732440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders.
    Prévot T; Sibille E
    Mol Psychiatry; 2021 Jan; 26(1):151-167. PubMed ID: 32346158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological treatment strategies targeting cognitive impairment associated with aging].
    Koh MT
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):157-9. PubMed ID: 22498679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippocampal GABA
    Neugebauer NM; Miyauchi M; Sato T; Tadano J; Akal H; Ardehali H; Meltzer HY
    Behav Brain Res; 2018 Apr; 342():11-18. PubMed ID: 29289597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA
    Rajagopal L; Huang M; Michael E; Kwon S; Meltzer HY
    Neuropsychopharmacology; 2018 Nov; 43(12):2468-2477. PubMed ID: 30093697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The α5-Containing GABA
    Mohamad FH; Has ATC
    J Mol Neurosci; 2019 Feb; 67(2):343-351. PubMed ID: 30607899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GABAA-BZR complex as target for the development of anxiolytic drugs.
    Trincavelli ML; Da Pozzo E; Daniele S; Martini C
    Curr Top Med Chem; 2012; 12(4):254-69. PubMed ID: 22204488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
    Atack JR
    Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of extra-synaptic α5-GABA
    Etherington LA; Mihalik B; Pálvölgyi A; Ling I; Pallagi K; Kertész S; Varga P; Gunn BG; Brown AR; Livesey MR; Monteiro O; Belelli D; Barkóczy J; Spedding M; Gacsályi I; Antoni FA; Lambert JJ
    Neuropharmacology; 2017 Oct; 125():353-364. PubMed ID: 28807671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.
    Xu MY; Wong AHC
    Acta Pharmacol Sin; 2018 May; 39(5):733-753. PubMed ID: 29565038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.
    Levin ED; McClernon FJ; Rezvani AH
    Psychopharmacology (Berl); 2006 Mar; 184(3-4):523-39. PubMed ID: 16220335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioural pharmacology of the α5-GABA
    Gacsályi I; Móricz K; Gigler G; Wellmann J; Nagy K; Ling I; Barkóczy J; Haller J; Lambert JJ; Szénási G; Spedding M; Antoni FA
    Neuropharmacology; 2017 Oct; 125():30-38. PubMed ID: 28694097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GABA-based therapeutic approaches: GABAA receptor subtype functions.
    Rudolph U; Möhler H
    Curr Opin Pharmacol; 2006 Feb; 6(1):18-23. PubMed ID: 16376150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline.
    Vinkers CH; Mirza NR; Olivier B; Kahn RS
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1217-33. PubMed ID: 20812877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists.
    Chambers MS; Atack JR; Bromidge FA; Broughton HB; Cook S; Dawson GR; Hobbs SC; Maubach KA; Reeve AJ; Seabrook GR; Wafford K; MacLeod AM
    J Med Chem; 2002 Mar; 45(6):1176-9. PubMed ID: 11881985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.
    Ballard TM; Knoflach F; Prinssen E; Borroni E; Vivian JA; Basile J; Gasser R; Moreau JL; Wettstein JG; Buettelmann B; Knust H; Thomas AW; Trube G; Hernandez MC
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):207-23. PubMed ID: 18936916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The α2β3γ2 GABA
    Spröte C; Richter F; Bauer A; Gerstenberger J; Richter A
    Eur J Pharmacol; 2016 Nov; 791():655-658. PubMed ID: 27693801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression.
    Russo E; Leo A; Crupi R; Aiello R; Lippiello P; Spiga R; Chimirri S; Citraro R; Cuzzocrea S; Constanti A; De Sarro G
    J Psychiatr Res; 2016 Jul; 78():1-10. PubMed ID: 27019134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.